3SBIO INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.08 HKD | +0.50% |
|
+9.35% | -19.15% |
| Apr. 22 | 3Sbio Inc. Announces Management Changes | CI |
| Apr. 15 | 3SBIO Gets China Nod for Use of Cancer Injection in Children with Thrombocytopenia | MT |
ETFs positioned on 3SBio Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.75% | 4 M€ | -27.92% | ||
| 0.63% | 2 M€ | -16.59% | - | |
| 0.23% | 2 M€ | -14.14% | ||
| 0.19% | 4 M€ | -11.56% | ||
| 0.15% | 3 M€ | -0.84% | - | |
| 0.10% | 11 M€ | +1.79% | ||
| 0.10% | 2 M€ | -.--% | ||
| 0.05% | 1 M€ | +3.49% | - | |
| 0.05% | 3 M€ | -.--% | - | |
| 0.02% | 441 M€ | +4.60% | - | |
| 0.02% | 2,808 M€ | +5.90% | - | |
| 0.02% | 149 M€ | +2.17% | - | |
| 0.02% | 117 M€ | +1.11% | - | |
| 0.02% | 4 M€ | -4.41% | - | |
| 0.01% | 7 M€ | +0.11% | - | |
| 0.01% | 31 M€ | +3.50% | - | |
| 0.00% | 7 M€ | +1.95% | - | |
| 0.00% | 34 M€ | +2.14% | - | |
| 0.00% | 389 M€ | +6.83% | - | |
| 0.00% | 147 M€ | +4.88% | - | |
| 0.00% | 34 M€ | +6.71% | - | |
| 0.00% | 39 M€ | +3.67% | - | |
| 0.00% | 302 M€ | +3.80% | - | |
| 0.00% | 108 M€ | +2.03% | - | |
| 0.00% | 17 M€ | +1.44% | - | |
| 0.00% | 15 M€ | +11.24% |
3SBio Inc. is an investment holding company mainly engaged in the the development, production, marketing and sale of pharmaceutical products. The Companyâs main products include recombinant human thrombopoietin (rhTPO) products, tumor necrosis factor (TNF)αinhibitor products and recombinant human erythropoietin (rhEPO) products. The products are sold under the name of TPIAO, Yisaipu, EPIAO and SEPO. The Company distributes its products within the domestic market and to overseas markets, including Sri Lanka, Dominican Republic and Thailand. The Companyâs subsidiaries include Collected Mind Limited, Hongkong Sansheng Medical Limited and Shenyang Sunshine Pharmaceutical Co., Ltd.. Through its subsidiaries, the Company is engaged in project management and consultation.
Sector
Pharmaceuticals
Calendar
2024-08-20
- Q2 2024 Earnings Release (Projected)
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
5.628
CNY
Average target price
6.887
CNY
Spread / Average Target
+22.36%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -19.15% | 1.85B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 1530 Stock
- Funds and ETFs 3SBio Inc.
